The Preemption Question at the Heart of Cosmetic Regulation
When Congress passed the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), it did more than overhaul federal oversight of cosmetic manufacturing, adverse event reporting, and ingredient safety substantiation. It also embedded an express preemption provision, codified at 21 U.S.C. § 379s, that bars states from imposing certain requirements related to cosmetic safety substantiation and adulteration standards that differ from federal law.
For years, this provision existed largely as a theoretical constraint. As of 2026, it has become the central battleground in cosmetic regulatory litigation. State legislatures—particularly in California, New York, Washington, and Illinois—have continued to advance ingredient bans, mandatory warning labels, and disclosure regimes that arguably intrude on territory MoCRA reserves for federal standard-setting. The resulting litigation is now producing a body of judicial reasoning that every cosmetics manufacturer, distributor, and retailer needs to understand.
The Statutory Architecture of MoCRA Preemption
MoCRA's preemption clause is narrower than many companies initially assumed. It does not create blanket federal exclusivity over all cosmetic regulation. Instead, it preempts state and local requirements that:
- Establish safety substantiation standards "different from" or "in addition to" federal requirements;
- Impose ingredient-specific safety determinations that federal law does not require; or
- Mandate labeling related to safety substantiation that departs from MoCRA's framework.
Critically, MoCRA preserves state authority in several areas, including:
- General product liability and tort claims;
- State disclosure laws not tied to safety substantiation (a distinction courts are actively wrestling with);
- Environmental and occupational safety regulations of general applicability; and
- Enforcement of a state's own consumer protection statutes where they do not conflict with federal cosmetic safety standards.
This carve-out structure is precisely where 2026's litigation has concentrated.
What the 2026 Rulings Reveal
Federal district courts addressing MoCRA preemption challenges in 2026 have converged on several recurring analytical themes, even where outcomes have diverged based on the specific state statute at issue.
1. Courts are distinguishing "safety" requirements from "disclosure" requirements.
The most consequential doctrinal development has been judicial willingness to separate state laws that impose independent safety judgments (preempted) from those that simply require disclosure of ingredient presence without asserting a safety conclusion (generally not preempted). Rulings addressing state "right to know" cosmetic ingredient disclosure statutes have largely upheld these laws, reasoning that disclosure obligations untethered to a state-specific safety standard do not conflict with MoCRA's substantiation framework.
2. Outright ingredient bans face the most serious preemption exposure.
Where state statutes prohibit the sale of cosmetics containing specific ingredients—rather than merely requiring disclosure—courts have shown greater receptivity to preemption arguments, particularly where the state ban is predicated on a state agency's independent safety determination that conflicts with, or supplements, FDA's substantiation framework under MoCRA. Several rulings have emphasized that MoCRA's legislative history reflects congressional intent to create uniform national safety standards, making conflicting or parallel state safety determinations especially vulnerable.
3. Warning label mandates occupy a contested middle ground.
State-mandated warning statements tied to specific ingredients (as opposed to general disclosure) have generated split outcomes. Courts appear to be applying a fact-intensive inquiry into whether the warning requirement functions as a substantive safety determination in the guise of a labeling rule. Where warning language implies an ingredient is unsafe at any exposure level—rather than simply informing consumers of presence—courts have been more willing to find conflict preemption.
4. Savings clause arguments have had mixed success.
States have increasingly argued that their statutes fall within MoCRA's preserved categories, particularly consumer protection and general disclosure authority. Courts have generally required states to demonstrate that their laws do not, in substance, function as safety substantiation regimes—a standard that has proven difficult to satisfy where legislative findings explicitly reference ingredient toxicity or health risk.
Why This Matters for Industry Stakeholders
The emerging judicial framework has direct compliance implications:
- Multi-jurisdictional labeling strategies must now account for a bifurcated legal landscape: disclosure-based state laws remain enforceable, while ingredient-specific safety bans and toxicity-based warnings carry meaningful preemption risk that companies may be able to leverage defensively.
- Litigation posture matters. Companies facing state enforcement actions or private consumer claims premised on ingredient bans should evaluate whether the underlying statute constitutes a "safety substantiation" requirement subject to MoCRA preemption—a threshold defense that is proving increasingly viable.
- FDA's own substantiation guidance is becoming central evidence. Courts are looking to FDA's implementing regulations and guidance documents under MoCRA to determine whether a state requirement duplicates, conflicts with, or exceeds federal standards.
- State legislatures are adapting. In response to early adverse rulings, several states have begun drafting new disclosure-focused statutes explicitly avoiding safety-conclusory language, suggesting the compliance target will continue to move.
Strategic Considerations Going Forward
The 2026 rulings do not yet resolve MoCRA preemption definitively; no circuit court has issued a controlling decision, and the doctrinal lines between disclosure and safety substantiation remain fact-specific. Companies should not assume broad immunity from state regulation, nor should they concede that all state ingredient restrictions survive.
Instead, the prudent approach is a rigorous, statute-by-statute preemption analysis—evaluating legislative findings, statutory text, and the practical function of any given state requirement against MoCRA's substantiation framework. As appellate review develops, this area of law will likely remain one of the most consequential compliance battlegrounds in cosmetic regulation for the remainder of the decade.
Companies operating in multiple states should treat MoCRA preemption analysis as a core component of product compliance review, not a peripheral legal question, particularly before reformulating products or accepting state enforcement demands that may exceed constitutional bounds.